English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 18 April 2019, 20:00 HKT/SGT
Share:
    

Source: ReShape Lifesciences Inc.
ReShape Lifesciences Announces Distribution in Australia

SAN CLEMENTE, CA & MELBOURNE, AU, Apr 18, 2019 - (ACN Newswire) - ReShape Lifesciences™, a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announces that as of April 1, 2019, the company was selling its LAP-BAND® product in the Australian market through a relationship with Satori Healthcare. Satori Healthcare is a medical device distributor focused on the Australian bariatric market.

The founder of Satori Healthcare has over 20 years of experience in the medical device industry, including 6 years of direct responsibility for LAP-BAND while it was owned by Allergan and Apollo Endosurgery respectively. Concurrent with this relationship, ReShape Lifesciences has fully taken over all distribution of the LAP-BAND product in Australia from Apollo Endosurgery, Inc. and will subsequently be recognizing revenue from sales of the product in Australia.

Over 120,000 LAP-BAND procedures have taken place in Australia since the product was launched in the country, making Australia one of the largest worldwide markets for LAP-BAND outside of the U.S. Australia was one of the early adopters of the LAP-BAND technology and has produced some of the strongest data and research on the product. According to the OECD 2017 Obesity Update, based on self-reported data, 27.9% of the Australian adult population are obese, the fifth highest obesity rate of any developed country.

About ReShape Lifesciences Inc

ReShape Lifesciences™ (OTCQB: RSLS) is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved LAP-BAND® Adjustable Gastric Banding System is designed to provide minimally invasive long-term treatment of severe obesity and is an alternative to more invasive surgical stapling procedures such as gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

Investor Contact:
Scott Youngstrom
Chief Financial Officer
ReShape Lifesciences Inc.
+1-949-429-6680 x106
[email protected]

SOURCE: ReShape Lifesciences Inc.

Topic: Press release summary
Sectors: BioTech, HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Accounting and Finance Show Hong Kong (25-26 September 2019) - Bringing Cutting-Edge Digital Innovations and Solutions to the Accountancy Sector  
July 23, 2019 20:02 HKT/SGT
Nearly 1 million visitors attend Hong Kong Book Fair  
July 23, 2019 20:00 HKT/SGT
Xiao-i AI Learning Platform 2-day Training on Smart Customer Service Successfully Held  
July 23, 2019 16:40 HKT/SGT
NPCI launches RuPay JCB Global Card  
July 23, 2019 16:30 HKT/SGT
Toyota to Bring Various Mobility to the Olympic and Paralympic Games Tokyo 2020  
July 23, 2019 12:42 HKT/SGT
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA  
July 23, 2019 11:37 HKT/SGT
Showa Denko Sets 2030 GHG Reduction Target Conforming to Global Standard  
July 23, 2019 11:00 HKT/SGT
Director-General of Investment Promotion visits Thailand to promote Hong Kong's business advantages  
July 23, 2019 10:30 HKT/SGT
Hong Kong Investment Promotion Chief visits Thailand to promote Hong Kong's business advantages  
July 23, 2019 10:30 HKT/SGT
Toyota Mobility Foundation to Study Vehicle Data to Inform Road Maintenance Inspection in Akaiwa City, Okayama  
July 23, 2019 10:07 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575